Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
Executive Summary
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.